2-哌啶基噻唑-5-甲醛 | 129865-52-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-哌啶基噻唑-5-甲醛
• 中文别名: 2-哌啶-1-噻唑-5-甲醛
• 英文名称: 2-(piperidin-1-yl)thiazole-5-carbaldehyde
• 英文别名: 2-(piperidin-1-yl)thiazol-2-carbaldehyde；2-Piperidino-1,3-thiazole-5-carbaldehyde；2-piperidin-1-yl-1,3-thiazole-5-carbaldehyde
• CAS: 129865-52-7
• 化学式: C₉H₁₂N₂OS
• 分子量: 196.273
• InChiKey: NWOAHSDBLWFXAG-UHFFFAOYSA-N

物化性质

• 熔点：
  48.5-49.5°C
• 沸点：
  342.0±34.0 °C(Predicted)
• 密度：
  1.257±0.06 g/cm3(Predicted)
• 溶解度：
  27.6 [ug/mL]
• 稳定性/保质期：

  如果按照规格使用和储存，则不会分解，也未有已知危险反应。请避免与氧化物或空气接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  61.4
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  2-哌啶基噻唑-5-甲醛 在 potassium carbonate 作用下， 以 乙醇 、 水 为溶剂， 生成 (1E,4E)-1-(1-isopropyl-1H-imidazol-2-yl)-5-(2-(piperidin-1-yl)thiazol-5-yl)penta-1,4-dien-3-one
  参考文献：
  名称：

  Asymmetric 1,5-diarylpenta-1,4-dien-3-ones: Antiproliferative activity in prostate epithelial cell models and pharmacokinetic studies

  摘要：

  To further engineer dienones with optimal combinations of potency and bioavailability, thirty-four asymmetric 1,5-diarylpenta-1,4-dien-3-ones (25-58) have been designed and synthesized for the evaluation of their in vitro anti-proliferative activity in three human prostate cancer cell lines and one non-neoplastic prostate epithelial cell line. All these asymmetric dienones are sufficiently more potent than curcumin and their corresponding symmetric counterparts. The optimal dienone 58, with IC50 values in the range of 0.03-0.12 mu M, is 636-, 219-, and 454-fold more potent than curcumin in three prostate cancer cell models. Dienones 28 and 49 emerged as the most promising asymmetric dienones that warrant further preclinical studies. The two lead compounds demonstrated substantially improved potency in cell models and superior bioavailability in rats, while exhibiting no acute toxicity in the animals at the dose of 10 mg/kg. Dienones 28 and 46 can induce PC-3 cell cycle regulation at the G(0)/G(1) phase. However, dienone 28 induces PC-3 cell death in a different way from 46 even though they share the same scaffold, indicating that terminal heteroaromatic rings are critical to the action of mechanism for each specific dienone. (C) 2017 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2017.05.062
• 作为产物：
  描述：

  2-氯噻唑 、 哌啶-1-甲醛 在 正丁基锂 作用下， 生成 2-哌啶基噻唑-5-甲醛
  参考文献：
  名称：

  Sawhney, Indu; Wilson, John R. H., Journal of the Chemical Society. Perkin transactions I, 1990, # 2, p. 329 - 331

  摘要：

  DOI：

文献信息

• [EN] VOLTAGE-GATED SODIUM CHANNEL BLOCKERS<br/>[FR] BLOQUEURS DES CANAUX SODIQUES VOLTAGE-DÉPENDANTS
  申请人：GLAXO GROUP LTD

  公开号：WO2013006596A1

  公开（公告）日：2013-01-10

  In general, the present invention relates to uses of voltage-gated sodium channel blocker compounds,, which include corresponding precursors, intermediates, monomers and dimers, corresponding pharmaceutical compositions, compound preparation and treatment methods for respiratory and respiratory tract diseases. In particular, the present invention also relates to methods and uses for treatment of respiratory or respiratory tract diseases, which comprises administering to a subject in need thereof an effective amount of a compound of the present invention.

  一般而言，本发明涉及使用电压门控钠通道阻滞剂化合物，包括相应的前体、中间体、单体和二聚体，相应的药物组合物，化合物制备和治疗方法，用于呼吸和呼吸道疾病。具体而言，本发明还涉及用于治疗呼吸或呼吸道疾病的方法和用途，包括向需要的受试者施用本发明化合物的有效量。
• VOLTAGE-GATED SODIUM CHANNEL BLOCKERS
  申请人：Boehm Jeffrey Charles

  公开号：US20130023541A1

  公开（公告）日：2013-01-24

  The present invention relates to voltage-gated sodium channel blocker intermediates, compounds and dimers, corresponding pharmaceutical compositions, compound preparation and treatment methods for respiratory or respiratory tract diseases.

  本发明涉及电压门控钠通道阻滞剂中间体、化合物和二聚体，相应的药物组合物、化合物制备和治疗呼吸或呼吸道疾病的方法。
• PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS
  申请人：DANA-FARBER CANCER INSTITUTE, INC.

  公开号：US20150291521A1

  公开（公告）日：2015-10-15

  The present invention provides compounds of Formula (I-A), (I-B), and (I-C), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting Myc (e.g., c-Myc) activity. The present invention further provides methods of using the compounds described herein for treating Myc-mediated disorders (e.g., cancer and other proliferative diseases). The present invention also provides assays for identifying Myc inhibitors.

  本发明提供了公式(I-A)、(I-B)和(I-C)的化合物，其药学上可接受的盐以及其制药组合物。本发明的化合物可用于抑制Myc（例如c-Myc）的活性。本发明还提供了使用本文所描述的化合物治疗Myc介导的疾病（例如癌症和其他增殖性疾病）的方法。本发明还提供了用于鉴定Myc抑制剂的检测方法。
• Pd-Catalyzed Amination of Base-Sensitive Five-Membered Heteroaryl Halides with Aliphatic Amines
  作者：Elaine C. Reichert、Kaibo Feng、Aaron C. Sather、Stephen L. Buchwald

  DOI：10.1021/jacs.2c13520

  日期：2023.2.15

  functional-group-tolerant method for the Pd-catalyzed C–N cross-coupling of five-membered heteroaryl halides with primary and secondary amines, an important but underexplored transformation. Coupling reactions of challenging, pharmaceutically relevant heteroarenes, such as 2-H-1,3-azoles, are reported in good-to-excellent yields. High-yielding coupling reactions of a wide set of five-membered heteroaryl

  我们报告了一种多功能且官能团耐受的方法，用于 Pd 催化五元杂芳基卤化物与伯胺和仲胺的 C-N 交叉偶联，这是一种重要但尚未充分探索的转化。据报道，具有挑战性的、药学相关的杂芳烃（例如 2- H -1,3-唑）的偶联反应具有良好至优异的产率。首次报道了多种五元杂芳基卤化物与空间要求高的 α-支化环胺和无环仲胺的高产率偶联反应。该方法广泛适用的关键是（1）中等强度的碱NaOTMS的协同组合，它限制了敏感五元杂芳烃的碱介导分解，最终导致催化剂失活，以及（2）使用GPhos 负载的 Pd 催化剂，可有效抵抗杂芳烃引起的催化剂失活，同时促进高效偶联，即使对于具有挑战性和空间要求的胺也是如此。展示了多种五元杂芳基卤化物和胺之间的交叉偶联反应，包括八个涉及密集功能化药物化学构件的例子。
• BENZOXAZOLE DERIVATIVES
  申请人：Tohoku University

  公开号：EP2103611A1

  公开（公告）日：2009-09-23

  It is intended to provide a benzoxazole derivative or a pharmaceutically acceptable salt or solvate thereof which is useful in the early diagnosis of a conformation disease; a composition or a kit containing the same for diagnosing a conformation disease; a medical composition for ttreating and/or preventing a conformation disease; and so on.

  本发明旨在提供一种苯并恶唑衍生物或其药学上可接受的盐或溶液，该衍生物或其药学上可接受的盐或溶液可用于构象疾病的早期诊断；一种含有该衍生物或其药学上可接受的盐或溶液的组合物或试剂盒，该组合物或试剂盒可用于构象疾病的诊断；一种用于治疗和/或预防构象疾病的医用组合物，等等。